A shadow market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.
Investigational Treatment Gaining Traction Via Social Media
Retatrutide, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing properties. Viewers are urged to message these profiles privately for source information, while also obtaining promotional offers.
Active Trade on Messaging Platforms
Additionally, a robust trade exists on messaging services, where communities with thousands of participants share “before and after” images, injection guides and claims of next-day British shipping. Vendors market the substance there before directing buyers to WhatsApp for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies indicate it could assist patients reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.
Healthcare Professionals Express Concerns
However, physicians and pharmacists have cautions that the distribution of what is still an unapproved medication in the UK is a cause for concern and could result in users injecting substances of uncertain source.
Some professionals stated the popularity for retatrutide could be linked to the increasing cost of approved weight loss treatments such as Mounjaro.
Regulatory Status and Enforcement
Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the British medical regulations.
Some influencers try to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and distribution can still breach medicines, marketing, and consumer regulations, risking fines, prosecution or imprisonment.
Service Reaction and Content Removal
Based on the social media company, the platform has taken down problematic material and prohibited related hashtags and query recommendations. The company said it was committed to keeping the service safe and investing in enhancing compliance measures.
Digital Trading Operations
Investigations also found groups with up to 9,000 participants selling retatrutide using Telegram's integrated search feature, which functions like a public directory. Typing “retatrutide” immediately brings up channels with thousands of users, populated with photos of slimming results, positive reviews and detailed instructions for preparing or administering at home.
Within moments of joining one community, a seller shared contact information, where most purchases take place. The seller sent an instruction manual and guaranteed delivery within two days. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another provided a image of a alleged testing documentation. None asked about weight, medical conditions or past usage.
Item Information and Pricing
Inside these groups, messages show black plastic packages with postal service stickers, stating to include new batches. One message stated: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens typically priced at £160 for 20mg. When questioned how much time a injector should be used, vendors give conflicting answers varying between a few weeks to “depends on your body”.
Platform Moderation and Safety Measures
A representative for Telegram said it actively monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Medical Expert Cautions
“Individuals are injecting substances they can’t verify. Even if the science behind this drug is sound, these online products may not include what they claim,” stated Jason Murphy, the head of pharmaceutical services at a pharmacy service.
A medical professional of Asda Online Doctor connected the increase in interest to recent price rises for authorized weight-loss drugs such as Mounjaro. “With prices rising, patients are turning to social media. But fake injections are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was clean,” she explained.
Her staff has previously encountered patients harmed by personal administration from unconfirmed sources. “We recognize the frustration, but purchasing from Telegram or communication platforms is taking chances with your health,” said the doctor. “These substances could be contaminated or incorrectly dosed.”
Manufacturer Statement
A representative from the pharmaceutical company stated the substance was in third stage research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they explained, noting that any item “falsely representing itself as a Lilly experimental substance not yet approved … may expose patients to potentially serious medical dangers”.
